New York Stock

[U.S. Featured Stocks] Braze: Revenue Falls Short of Expectations, Raising Growth Concerns… Stock Price Down 19%

김카니
2026-09-10 02:01:52
[Edaily Reporter Kim Kani] Shares of Braze (BRZE), a customer engagement platform provider, are plummeting as concerns about its growth prospects have come to the fore following the announcement of revenue that fell short of market expectations.
According to CNBC on the 4th (local time), Braze’s reported quarterly revenue fell short of market expectations. This suggests that the market is growing increasingly wary of the company’s future growth trajectory, as Braze—which supports digital marketing between customers and businesses—has failed to meet market expectations for revenue growth.
On the other hand, earnings per share (EPS) for the same period exceeded market forecasts, indicating better-than-expected profitability. However, investors appear to be focusing more on the below-expectation revenue than on the improvement in EPS. As the revenue shortfall fuels concerns about earnings growth, Braze’s stock price is trading at $24.54 as of today (local time), down 19.04% from the previous day.

Economy

Corporation

IT·Science

Economy

Lisa Su Meets with Jeon Young-hyun for 3 Hours… “Broad Partnership” for Foundry Collaboration

Lisa Su, Chairwoman and CEO of AMD, concluded a meeting lasting over three hours with Jeon Young-hyun, President and CEO of SamsungElectronics and Vice Chairman in charge of the Device Solutions (DS) …
2026-10-07 20:35:47

Corporation

South Korea Enters the 160 Trillion Global Obesity Drug Market… HanmiGlobal Co., Ltd’s “Epe” Becomes First Domestically Developed Drug to Receive Approval

Epfeglenatide, developed by HanmiPharm, has received approval from the Ministry of Food and Drug Safety as the first domestically developed GLP-1-based obesity treatment. With this approval, Korea has…
2026-10-07 19:34:02

IT·Science

A Twist in the Story of the New Drug Rejected by Sanofi… Hanmi’s “Epe” Becomes the First Domestically Developed GLP-1 Weight-Loss Drug to Receive Approval

A new domestically developed drug has emerged to compete in the obesity treatment market, which is currently dominated by global pharmaceutical companies. With HanmiPharm’s efeglenatide receiving mark…
2026-10-07 18:22:02